iRhythm Technologies, a digital healthcare solutions company focused on the advancement of cardiac care, amended its existing debt facility with Silicon Valley Bank. The agreement improves upon the pricing and terms of iRhythm’s existing credit facility.
The amended credit facility is non-dilutive and consists of a term loan of up to $75 million and a revolving credit facility of up to $25 million. Thirty-five million dollars of the term loan has been drawn down at closing to pay in full the approximately $18.5 million outstanding on the term loan under the existing credit facility and to fund working capital. The remaining $40 million of the term loan will remain available for iRhythm to draw through Dec. 31, 2023, subject to applicable conditions. The revolving credit line availability is subject to a borrowing base comprised of the company’s accounts receivable. The amended credit facility will mature on March 1, 2027.
“We are pleased to further strengthen our cash position with non-dilutive financing at a reduced cost of capital and an extended maturity compared to our prior loan agreement,” Quentin Blackford, president and CEO of iRhythm, said. “This amendment to our existing debt facility provides us with continued financial stability and flexibility to execute upon our core strategies of accelerating growth in our core market and expanding our opportunities in adjacent ones.”
“Silicon Valley Bank is thrilled to continue partnering with iRhythm to support their mission to advance cardiac care with innovative and clinically actionable heart monitoring solutions,” Kristina Peralta, senior vice president of life science and healthcare at Silicon Valley Bank, said.
